Tryp Therapeutics Inc (TSE:TRYP) has released an update.
Tryp Therapeutics Inc. shareholders have resoundingly supported an arrangement with Exopharm Limited, with 99.92% of votes in favor at the recent annual meeting. The Supreme Court of British Columbia has given its final approval, moving the company closer to finalizing the deal, anticipated by late March 2024. This strategic move aims to bolster Tryp’s efforts in developing novel treatments for conditions with unmet medical needs, leveraging their proprietary psilocin-based therapies.
For further insights into TSE:TRYP stock, check out TipRanks’ Stock Analysis page.
